go to content

FDA Panel Recommends Approval Of "Female Viagra"

However, the panel of government experts said their approval was contingent on certain safety conditions being met.

Posted on

A panel of experts at the Food and Drug Administration have given preliminary approval to a drug that some have called the "female Viagra."

Flibanserin, which is manufactured by Sprout Pharmaceuticals Inc., is designed to treat premenopausal women who struggle with a low sex drive.

The panel voted to approve the drug by a vote of 18-6, an FDA spokeswoman told BuzzFeed News.

However, their "yes" vote was contingent on the drug maker implementing "certain risk management options beyond labeling." Six experts voted not to approve the drug, and none of the experts voted to approve the drug without these contingencies.

If it is approved, it would be the first drug on the market to treat low libido for women.

However, as BuzzFeed News reported in February, the drug has been rejected by the FDA twice before.

In 2013, the FDA rejected the drug because of concerns that its side effects, such as sedation, dizziness and nausea, did not outweigh its benefits.

The agency is not under any obligation to listen to the panel's advice when it considers the drug in August, but the government usually follows what the panel decides, according to the Associated Press.

Stephanie McNeal is a social news editor for BuzzFeed News and is based in New York.

Contact Stephanie McNeal at stephanie.mcneal@buzzfeed.com.

Got a confidential tip? Submit it here.